NO20072099L - Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft - Google Patents

Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft

Info

Publication number
NO20072099L
NO20072099L NO20072099A NO20072099A NO20072099L NO 20072099 L NO20072099 L NO 20072099L NO 20072099 A NO20072099 A NO 20072099A NO 20072099 A NO20072099 A NO 20072099A NO 20072099 L NO20072099 L NO 20072099L
Authority
NO
Norway
Prior art keywords
bone
treatment
cancer
epothilones
tumors
Prior art date
Application number
NO20072099A
Other languages
English (en)
Inventor
Ulrich Klar
Jens Hoffmann
Hubertus Pietsch
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072099(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20072099L publication Critical patent/NO20072099L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelsen av epotiloner ved behandlingen av benmetastaser og bentumorer eller benkreftfiormer, nærmere bestemt ved behandling, fiorhindring eller lindring av benmetastaser hos en kreftpasient.
NO20072099A 2004-09-24 2007-04-23 Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft NO20072099L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers
PCT/EP2005/010400 WO2006032537A2 (en) 2004-09-24 2005-09-22 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
NO20072099L true NO20072099L (no) 2007-04-23

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072099A NO20072099L (no) 2004-09-24 2007-04-23 Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft

Country Status (21)

Country Link
EP (2) EP1640004A1 (no)
JP (1) JP2008514569A (no)
KR (1) KR20070054214A (no)
CN (1) CN101065126A (no)
AR (1) AR051035A1 (no)
AU (1) AU2005287477A1 (no)
BR (1) BRPI0516080A (no)
CA (1) CA2580215A1 (no)
CR (1) CR9064A (no)
EC (1) ECSP077390A (no)
GT (1) GT200500267A (no)
IL (1) IL181785A0 (no)
MX (1) MX2007003503A (no)
NO (1) NO20072099L (no)
PA (1) PA8646201A1 (no)
PE (1) PE20060695A1 (no)
RU (1) RU2007115162A (no)
TW (1) TW200626150A (no)
UY (1) UY29136A1 (no)
WO (1) WO2006032537A2 (no)
ZA (1) ZA200703306B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
PT1140944E (pt) * 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
PE20010116A1 (es) * 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
AU775373B2 (en) * 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
EP1503756B1 (en) * 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
JP2006510626A (ja) * 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
AR051035A1 (es) 2006-12-13
KR20070054214A (ko) 2007-05-28
IL181785A0 (en) 2007-07-04
WO2006032537A2 (en) 2006-03-30
MX2007003503A (es) 2007-08-17
CN101065126A (zh) 2007-10-31
BRPI0516080A (pt) 2008-08-19
ECSP077390A (es) 2007-05-30
AU2005287477A1 (en) 2006-03-30
TW200626150A (en) 2006-08-01
ZA200703306B (en) 2010-06-30
EP1809281A2 (en) 2007-07-25
CA2580215A1 (en) 2006-03-30
PE20060695A1 (es) 2006-08-03
EP1640004A1 (en) 2006-03-29
WO2006032537A3 (en) 2006-05-04
JP2008514569A (ja) 2008-05-08
GT200500267A (es) 2006-06-06
RU2007115162A (ru) 2008-11-20
PA8646201A1 (es) 2006-11-09
UY29136A1 (es) 2006-04-28
CR9064A (es) 2007-10-01

Similar Documents

Publication Publication Date Title
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
WO2007013950A3 (en) Combination therapy of her expressing tumors
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
ATE408601T1 (de) Fredericamycin-derivate
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
EA200800762A1 (ru) Предотвращение гипотензии и стабилизация кровяного давления у гемодиализных пациентов
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2006015035A8 (en) Useful compounds for hpv infection
ATE448232T1 (de) Substituierte heterozyklen
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
NO20065780L (no) Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor
NO20072099L (no) Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft
EA200801425A1 (ru) Диазепиноны
NO20060420L (no) 2-aminobenzoylderivater
PL1843771T3 (pl) Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application